Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307471 | 0.89 | FGFR1 (0.49) | HPGDLMNAALDH1A1FGFR1SMN1; SMN2 | |
| SCHEMBL1307784 | 0.84 | HCAR3 (0.52) | HCAR3HPGDLMNAALDH1A1FGFR1 | |
| SCHEMBL3438336 | 0.83 | HCAR3 (0.61) | HCAR3HPGDLMNAALDH1A1FGFR1 | |
| SCHEMBL12053612 | 0.82 | CNR2 (0.45) | HPGD | |
| SCHEMBL1306903 | 0.80 | HPGD (0.42) | HPGDLMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL15183085 | 0.79 | BRD4 (0.47) | HCAR3HPGDLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30138443 | 0.79 | HCAR3 (0.58) | HCAR3HPGDLMNAALDH1A1FGFR1 | |
| SCHEMBL3436680 | 0.79 | HCAR3 (0.58) | HCAR3HPGDLMNAALDH1A1FGFR1 | |
| SCHEMBL15174662 | 0.78 | HSD17B10 (0.44) | HCAR3HPGDLMNAALDH1A1FGFR1 | |
| SCHEMBL2937848 | 0.78 | HCAR3 (0.55) | HCAR3HPGDLMNAALDH1A1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | claimed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| CN-101355938-A | Pharmaceutical use of substituted amides | TRANSTECH PHARMA INC (US) | 2009-01-28 | — | — | CN | disclosed |
| EP-1945207-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | Transtech Pharma, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | HCAR3 506/4885HPGD 27/4885LMNA 3649/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | HCAR3 488/4885HPGD 28/4885LMNA 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.